Foresite Capital Management IV, LLC Diversified Active

CIK: 0001704132 · Show all filings

Period: Q4 2018 (← Previous) (Next →)

Filing Date: Feb 13, 2019

Total Value ($000): $217,868 (100.0% shares, 0.0% debt)

Holdings (18)

Biohaven Pharmaceutical Holding Company Ltd. 14.5%
Value ($000) $31,651 Shares 855,900 Est. Cost $26.07 Unrealized
INSM Insmed Incorporated 11.9%
Value ($000) $25,941 Shares 1,977,236 Est. Cost $26.83 Unrealized -40.5%
Myokardia, Inc. 10.9%
Value ($000) $23,776 Shares 486,624 Est. Cost $45.40 Unrealized
CymaBay Therapeutics, Inc. 9.5%
Value ($000) $20,708 Shares 2,631,258 Est. Cost $8.89 Unrealized
Immunomedics, Inc. 7.9%
Value ($000) $17,201 Shares 1,205,363 Est. Cost $17.13 Unrealized
ASND Ascendis Pharma A/S 7.1%
Value ($000) $15,376 Shares 245,424 Est. Cost $40.06 Unrealized
REPL Replimune Group, Inc. 5.6%
Value ($000) $12,297 Shares 1,229,656 Est. Cost $17.53 Unrealized -22.9%
RYTM Rhythm Pharmaceuticals, Inc. 4.9%
Value ($000) $10,752 Shares 400,000 Est. Cost $27.09 Unrealized +2.0%
OptiNose, Inc. 4.9%
Value ($000) $10,593 Shares 1,708,545 Est. Cost $17.42 Unrealized
Orchard Therapeutics PLC 4.8%
Value ($000) $10,513 Shares 668,361 Est. Cost $15.73 Unrealized
Aerie Pharmaceuticals, Inc. 4.3%
Value ($000) $9,452 Shares 261,823 Est. Cost $36.10 Unrealized
ABUS Arbutus Biopharma Corporation 2.8%
Value ($000) $6,060 Shares 1,582,275 Est. Cost $5.62 Unrealized -12.3%
Eidos Therapeutics, Inc. 2.7%
Value ($000) $5,941 Shares 431,781 Est. Cost $14.82 Unrealized
ACRS Aclaris Therapeutics, Inc. 2.5%
Value ($000) $5,529 Shares 748,132 Est. Cost $18.71 Unrealized -44.9%
Portola Pharmaceuticals, Inc. 2.2%
Value ($000) $4,880 Shares 250,000 Est. Cost $19.52 Unrealized
SIBN SI-BONE, Inc. 2.0%
Value ($000) $4,295 Shares 205,621 Est. Cost $18.92 Unrealized 0.0%
Kiniksa Pharmaceuticals, Ltd. 0.8%
Value ($000) $1,796 Shares 63,922 Est. Cost $17.35 Unrealized
CYTK Cytokinetics Incorporated 0.5%
Value ($000) $1,107 Shares 175,148 Est. Cost $7.34 Unrealized 0.0%